Esthesioneuroblastoma

Last edited and medically reviewed by on

Synonyms
esthesioneuroblastoma, Olfactorius-Neuroblastom, olfactory neuroblastoma
ICD-10
C30.0
ICD-11
2C20.3, XH50L1

Esthesioneuroblastoma is a rare malignant neoplasm originating in the nasal cavities.

Epidemiology

Esthesioneuroblastoma is an extremely rare Tumor, with an incidence of approximately 0.4 per 1,000,000 people[^1].

Imaging

On MRI, esthesioneuroblastomas demonstrate intermediate to high signal intensity on a T1-weighted sequence and show heterogeneous contrast enhancement[^2]. The signal characteristics on MRI may resemble those of a Meningioma [^2].

Esthesioneuroblastoma on MRI
Coronal (A) T1-weighted, (B) contrast-enhanced, and (C) T2 MRI images. The T2-weighted sequence with the double arrow shows a peritumoral cyst. Figure adapted from Arthur B. Dublin et al. 2016.

Classification

Pathology

The Hyams grading system is used as a pathological classification, which is used to define all upper respiratory tract carcinomas. Hyams grading comprises four grades; meta-analyses have shown that Hyams grades 1 and 2 indicate a benign disease course, whereas Hyams grades 3 and 4 indicate an unfavorable disease course[^2].

Clinical

The Kadish classification is also used for classification according to the anatomical extent of the tumor. Other clinical classifications include those by Biller et al.[^3] or by Dulguerov and Calcattera[^4].

Prognosis

The overall median survival for esthesioneuroblastoma is typically 7.2 ± 0.7 years[^5]. Mean [progression-free survival](\/lexikon\/progressionsfreies-ueberleben) is 4.8 ± 0.7 years[^5]. The 5- and 10-year survival rates are 63% and 40%, respectively[^5].

Editorial transparency

Authorship & revisions

Who created and updated this article, and which changes are documented.

Article created by
Last edited:
on
Revision history
9 edits · 1 contributor
Author list:
Show revision history 9 entries

9 edits by 1 author

Edit · Alaric Steinmetz ·

No content change recorded

Edit · Alaric Steinmetz · (+8 −8)
  • Text changed: “Esthesioneuroblastoma is a rare malignant neoplasm arising from the nasal cavities.”“Esthesioneuroblastoma is a rare malignant neoplasm originating in the nasal cavities.”
  • Text changed: “Esthesioneuroblastoma is an extremely rare Tumor , occurring with an incidence of approximately 0.4 per 1,000,000 people[^1].”“Esthesioneuroblastoma is an extremely rare Tumor , with an incidence of approximately 0.4 per 1,000,000 people[^1].”
  • Text changed: “On MRI, esthesioneuroblastomas show medium to high signal intensity on a T1-weighted sequence and demonstrate heterogeneous contrast enhancement[^2]. The signal characteristics on MRI may resemble those of a Meningioma [^2].”“On MRI, esthesioneuroblastomas demonstrate intermediate to high signal intensity on a T1-weighted sequence and show heterogeneous contrast enhancement[^2]. The signal characteristics on MRI may resemble those of a Meningioma [^2].”
  • Text changed: “The Hyams grading system is used for pathological classification and is applied to all upper respiratory tract carcinomas. Hyams grading consists of four grades; meta-analyses have shown that Hyams grades 1 and 2 suggest a benign disease course, whereas Hyams grades 3 and 4 suggest an unfavorable disease course[^2].”“The Hyams grading system is used as a pathological classification, which is used to define all upper respiratory tract carcinomas. Hyams grading comprises four grades; meta-analyses have shown that Hyams grades 1 and 2 indicate a benign disease course, whereas Hyams grades 3 and 4 indicate an unfavorable disease course[^2].”
  • Text changed: “The Kadish classification is also used to categorize tumors according to their anatomical extent. Other clinical classification systems include those described by Biller et al.[^3] and by Dulguerov and Calcattera[^4].”“The Kadish classification is also used for classification according to the anatomical extent of the tumor. Other clinical classifications include those by Biller et al.[^3] or by Dulguerov and Calcattera[^4].”
  • Text changed: “The overall median prognosis for esthesioneuroblastoma is typically 7.2 ± 0.7 years[^5]. The mean [progression-free survival](\/lexikon\/progressionsfreies-ueberleben) is 4.8 ± 0.7 years[^5]. The 5- and 10-year survival rates are 63% and 40%, respectively[^5].”“The overall median survival for esthesioneuroblastoma is typically 7.2 ± 0.7 years[^5]. Mean [progression-free survival](\/lexikon\/progressionsfreies-ueberleben) is 4.8 ± 0.7 years[^5]. The 5- and 10-year survival rates are 63% and 40%, respectively[^5].”
Edit · Alaric Steinmetz ·

No content change recorded

Edit · Alaric Steinmetz · (+183 −0)

No content change recorded

Edit · Alaric Steinmetz · (+0 −181)

No content change recorded

Edit · Alaric Steinmetz · (+40 −38)
  • Text added: “Prognosis”
  • Text added: “The median overall survival for esthesioneuroblastoma is typically 7.2 ± 0.7 years[^5]. Mean [progression-free survival](/lexikon/progressionsfreies-ueberleben) is 4.8 ± 0.7 years[^5]. The 5- and 10-year survival rates are 63% and 40%, respectively[^5].”
  • Text changed: “Esthesioneuroblastoma is a rare malignant neoplasm arising from the nasal cavities.”“Esthesioneuroblastoma is a rare malignant neoplasm originating in the nasal cavities.”
  • Text changed: “Esthesioneuroblastoma is an extremely rare Tumor , occurring with an incidence of approximately 0.4 per 1,000,000 people[^1].”“Esthesioneuroblastoma is an extremely rare Tumor , with an incidence of approximately 0.4 per 1,000,000 people[^1].”
  • Text changed: “On MRI, esthesioneuroblastomas appear in a T1-weighted sequence with moderate to high signal intensity, and heterogeneous contrast enhancement occurs[^2]. The signal characteristics on MRI may resemble those of a Meningioma [^2].”“On MRI, esthesioneuroblastomas demonstrate moderate to high signal intensity on a T1-weighted sequence and heterogeneous contrast enhancement[^2]. The signal characteristics on MRI may resemble those of a Meningioma [^2].”
  • Text changed: “Hyams grading is used for pathological classification and is applied to define all upper respiratory tract carcinomas. Hyams grading consists of four grades, with meta-analyses demonstrating that Hyams grades 1 and 2 indicate a benign disease course, whereas Hyams grades 3 and 4 indicate an unfavorable disease course[^2].”“The Hyams grading system is used as the pathological classification, which is used to define all upper respiratory tract carcinomas. Hyams grading comprises four grades, with meta-analyses showing that Hyams grades 1 and 2 indicate a benign disease course, whereas Hyams grades 3 and 4 indicate an unfavorable disease course[^2].”
  • Text changed: “The Kadish classification is also used to classify tumors according to their anatomical extent. Other clinical classifications include those described by Biller et al.[^3] and by Dulguerov and Calcaterra[^4].”“The Kadish Classification is also used for classification according to the anatomical extent of the tumor. Other clinical classifications are those of Biller et al.[^3] or Dulguerov and Calcaterra[^4].”
  • Citation added: “Theilgaard, Sune A., et al. "Esthesioneuroblastoma: a Danish demographic study of 40 patients registered between 1978 and 2000." Acta oto-laryngologica 123.3 (2003): 433-439.”
  • Citation added: “Biller HF, Lawson W, Sachdev VP, et al. Esthesioneuroblastoma: surgical treatment without radiation. Laryngoscope. 1990;100:1199-1201”
  • Citation added: “Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970-1990. Laryngoscope. 1992;102:843-849”
  • Citation added: “Van Gompel JJ, Giannini C, Olsen KD, et al. Long-term outcome of esthesioneuroblastoma: hyams grade predicts patient survival. J Neurol Surg B Skull Base. 2012;73:331-336”
Edit · Alaric Steinmetz · (+29 −30)
  • Text added: “Pathology”
  • Text added: “Hyams grading is used for pathological classification and is applied to define all upper respiratory tract carcinomas. Hyams grading consists of four grades, with meta-analyses demonstrating that Hyams grades 1 and 2 indicate a benign disease course, whereas Hyams grades 3 and 4 indicate an unfavorable disease course[^2].”
  • Text added: “Clinical”
  • Text added: “The Kadish classification is also used to classify tumors according to their anatomical extent. Other clinical classifications include those described by Biller et al.[^3] and by Dulguerov and Calcaterra[^4].”
  • Text removed: “Pathology”
  • Text removed: “Hyams grading is used for pathological classification and is applied to define all upper respiratory tract carcinomas. Hyams grading consists of four grades, with meta-analyses demonstrating that Hyams grades 1 and 2 indicate a benign disease course, whereas Hyams grades 3 and 4 indicate an unfavorable disease course[^2].”
  • Text removed: “Clinical”
  • Text removed: “The Kadish classification is also used to classify tumors according to their anatomical extent. Other clinical classifications include those described by Biller et al.[^3] and by Dulguerov and Calcaterra[^4].”
  • Text removed: “Prognosis”
Edit · Alaric Steinmetz ·

No content change recorded

Article created on · Alaric Steinmetz

Image viewer

Image

Open original